<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54754</article-id><article-id pub-id-type="doi">10.7554/eLife.54754</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Metabolic response of blood vessels to TNFα</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-170521"><name><surname>Junaid</surname><given-names>Abidemi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8562-7942</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170522"><name><surname>Schoeman</surname><given-names>Johannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0905-2467</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170523"><name><surname>Yang</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3394-7570</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170524"><name><surname>Stam</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170525"><name><surname>Mashaghi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170526"><name><surname>van Zonneveld</surname><given-names>Anton Jan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-43591"><name><surname>Hankemeier</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7871-2073</contrib-id><email>hankemeier@lacdr.leidenuniv.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University</institution><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Department of Internal Medicine (Nephrology), Leiden University Medical Center</institution><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center</institution><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing Editor</role><aff><institution>Flinders Medical Centre</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>08</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e54754</elocation-id><history><date date-type="received" iso-8601-date="2019-12-27"><day>27</day><month>12</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-08-02"><day>02</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Junaid et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Junaid et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54754-v2.pdf"/><abstract><p>TNFα signaling in the vascular endothelium elicits multiple inflammatory responses that drive vascular destabilization and leakage. Bioactive lipids are main drivers of these processes. In vitro mechanistic studies of bioactive lipids have been largely based on two-dimensional endothelial cell cultures that, due to lack of laminar flow and the growth of the cells on non-compliant stiff substrates, often display a pro-inflammatory phenotype. This complicates the assessment of inflammatory processes. Three-dimensional microvessels-on-a-chip models provide a unique opportunity to generate endothelial microvessels in a more physiological environment. Using an optimized targeted liquid chromatography–tandem mass spectrometry measurements of a panel of pro- and anti-inflammatory bioactive lipids, we measure the profile changes upon administration of TNFα. We demonstrate that bioactive lipid profiles can be readily detected from three-dimensional microvessels-on-a-chip and display a more dynamic, less inflammatory response to TNFα, that resembles more the human situation, compared to classical two-dimensional endothelial cell cultures.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>In a range of conditions called autoimmune diseases, the immune system attacks the body rather than foreign elements. This can cause inflammation that is harmful for many organs. In particular, immune cells can produce excessive amounts of a chemical messenger called tumor necrosis factor alpha (TNFα for short), which can lead to the release of fatty molecules that damage blood vessels.</p><p>This process is normally studied in blood vessels cells that are grown on a dish, without any blood movement. However, in this rigid 2D environment, the cells become ‘stressed’ and show higher levels of inflammation than in the body. This makes it difficult to assess the exact role that TNFα plays in disease.</p><p>A new technology is addressing this issue by enabling scientist to culture blood vessels cells in dishes coated with gelatin. This allows the cells to organize themselves in 3D, creating tiny blood vessels in which fluids can flow. However, it was unclear whether these ‘microvessels-on-a-chip’ were better models to study the role of TNFα compared to cells grown on a plate.</p><p>Here, Junaid et al. compared the levels of inflammation in blood vessels cells grown in the two environments, showing that cells are less inflamed when they are cultured in 3D. In addition, when the artificial 3D-blood vessels were exposed to TNFα, they responded more like real blood vessels than the 2D models. Finally, experiments showed that it was possible to monitor the release of fatty molecules in this environment. Together, this work suggests that microvessels-on-a-chip are better models to study how TNFα harms blood vessels.</p><p>Next, systems and protocols could be develop to allow automated mass drug testing in microvessels-on-a-chip. This would help scientists to quickly screen thousands of drugs and find candidates that can protect blood vessels from TNFα.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>metabolomics</kwd><kwd>oxidative stress</kwd><kwd>inflammation</kwd><kwd>microvessels-on-a-chip</kwd><kwd>endothelial cells</kwd><kwd>3D cell culture</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002996</institution-id><institution>Hartstichting</institution></institution-wrap></funding-source><award-id>RECONNECT CVON Groot</award-id><principal-award-recipient><name><surname>Junaid</surname><given-names>Abidemi</given-names></name><name><surname>van Zonneveld</surname><given-names>Anton Jan</given-names></name><name><surname>Hankemeier</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>114022501</award-id><principal-award-recipient><name><surname>Junaid</surname><given-names>Abidemi</given-names></name><name><surname>van Zonneveld</surname><given-names>Anton Jan</given-names></name><name><surname>Hankemeier</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003246</institution-id><institution>Nederlandse Organisatie voor Wetenschappelijk Onderzoek</institution></institution-wrap></funding-source><award-id>16249</award-id><principal-award-recipient><name><surname>Mashaghi</surname><given-names>Alireza</given-names></name><name><surname>Hankemeier</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Health~Holland</institution></institution-wrap></funding-source><award-id>TKI METABOCHIP project</award-id><principal-award-recipient><name><surname>Hankemeier</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The metabolic readout of endothelial function in the microvessels-on-a-chip facilitates mechanistic studies and detection of biomarkers for microvascular diseases in a physiological relevant environment.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumor necrosis factor-α (TNFα) is a central mediator of the inflammatory response (<xref ref-type="bibr" rid="bib39">Sedger and McDermott, 2014</xref>). TNFα can be generated by monocytes or macrophages and activates endothelial cells at sites of tissue injury or infection through TNF receptor-1 (TNFR1) (<xref ref-type="bibr" rid="bib9">Chimen et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Torres-Castro et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Green et al., 2016</xref>). Following activation, the endothelium elicits a multitude of local responses such as vascular leakage, leukocyte adhesion and coagulation that together are essential to the physiological homeostatic responses to anti-microbial immunity.</p><p>However, chronic exposure to adverse metabolic and hemostatic risk factors (<xref ref-type="bibr" rid="bib23">Masi et al., 2018</xref>), obesity (<xref ref-type="bibr" rid="bib12">Engin, 2017</xref>), or disease states such as kidney disease (<xref ref-type="bibr" rid="bib33">Rabelink et al., 2010</xref>) or rheumatoid arthritis (<xref ref-type="bibr" rid="bib46">van Zonneveld et al., 2010</xref>) are all associated with a systemic inflammatory condition and elevated circulating levels of TNFα. As a consequence, TNFα signaling induces the generation of high levels of free radicals in the vascular endothelium that, when excessive, can deplete the cellular anti-oxidant defense systems and lead to a state of oxidative stress and vascular dysfunction (<xref ref-type="bibr" rid="bib31">Pisoschi and Pop, 2015</xref>).</p><p>Mechanistically, TNFα signaling in endothelial cells involves the activation of NFκB and results in the increased synthesis of reactive oxygen species (ROS) from a number of sources such as mitochondria, NADPH oxidase, uncoupled eNOS, xanthine oxidase, and peroxidases (<xref ref-type="bibr" rid="bib7">Cai and Harrison, 2000</xref>; <xref ref-type="bibr" rid="bib6">Blaser et al., 2016</xref>). On its turn, elevated ROS can lead to the generation of bioactive lipids directly or indirectly, such as prostaglandins, isoprostanes, lysophosphatidic acid classes, sphingolipids and platelet activating factor (PAF). Under physiologic conditions, in concert with the transcriptional regulation of a plethora of inflammatory genes (<xref ref-type="bibr" rid="bib32">Poussin et al., 2020</xref>), these bioactive lipids are critically involved in the first response of endothelial cells to environmental changes, controlling vascular permeability and platelet- and leukocyte adhesion. Also, in fore mentioned patients, isoprostanoids such as 8-epiPGF2α are generated by peroxidation during conditions of oxidative stress (<xref ref-type="bibr" rid="bib24">Morrow et al., 1990</xref>) and serve as gold standard oxidative stress plasma markers (<xref ref-type="bibr" rid="bib34">Ridker, 2004</xref>) associating with an increased risk for cardiovascular disease and its underlying causes (<xref ref-type="bibr" rid="bib25">Moutzouri et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Vassalle et al., 2004</xref>).</p><p>The central role of TNFα in many disease states has identified this cytokine as an important therapeutic target to counteract vascular inflammation (<xref ref-type="bibr" rid="bib39">Sedger and McDermott, 2014</xref>; <xref ref-type="bibr" rid="bib13">Esposito and Cuzzocrea, 2009</xref>) and several TNFα blockers have been approved by the FDA and have been effective for the suppression of immune-system diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis (<xref ref-type="bibr" rid="bib1">Ackerman et al., 2016</xref>).</p><p>Following the success of the TNFα antagonists, a deeper understanding of the impact of oxidative stress on the homeostasis of the human vascular endothelium may yield more specific targets for inflammatory diseases affecting the vasculature. To that end, many in vitro mechanistic studies have relied on static, two-dimensional (2D) cultures of primary endothelial cells such as those derived from human umbilical veins (HUVECs) (<xref ref-type="bibr" rid="bib17">Jaffe et al., 1973</xref>). However, in recent years it has become increasingly apparent that these cultures reflect a ‘stressed’ endothelial phenotype due to the lack of their native environmental cues. In vitro, endothelial cells are usually cultured on surfaces such as plastics and glass that are much stiffer than natural substrates such as the extracellular matrix. Recent studies demonstrated that primary endothelial cells on a hard substrate adopt a pro-inflammatory phenotype (<xref ref-type="bibr" rid="bib41">Stroka and Aranda-Espinoza, 2011</xref>; <xref ref-type="bibr" rid="bib16">Huveneers et al., 2015</xref>). Vascular stiffness is strongly associated with vascular disorders such as arterial hypertension, kidney disease and atherosclerosis (<xref ref-type="bibr" rid="bib16">Huveneers et al., 2015</xref>). Likewise, native microvessels need laminar shear to maintain a quiescent phenotype and the lack of laminar shear stress in static cultures converts endothelial cells to a pro-inflammatory ‘diseased’ phenotype (<xref ref-type="bibr" rid="bib3">Baeyens et al., 2016</xref>).</p><p>Novel microfluidics-based perfused three-dimensional (3D) microvessels-on-a-chip models provide a unique opportunity to generate endothelial microvessels in a more physiological environment. We employed a gelatin coated 3D microvessels-on-a-chip model in which endothelial cells are organized in a tube-like architecture, with densities of cells and area to volume ratios that are closer to a physiological condition than those in typical 2D culture.</p><p>To assess whether these 3D microvessels display a more anti-inflammatory phenotype, we used an optimized targeted liquid chromatography–tandem mass spectrometry measurements of a panel of pro- and anti-inflammatory bioactive lipids and generated expression profiles both in TNFα treated microvessels under flow as well as in 2D endothelial cell cultures under static condition. We demonstrate bioactive lipid profiles can be readily detected from single microvessels and display a more dynamic, less inflammatory response to TNFα, that resembles more the human situation, compared to classical 2D endothelial cell cultures.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Bioactive lipids generated by 3D microvessels-on-a-chip can be measured by UPLC-MS/MS</title><p>In this paper, we present a novel set-up to measure the metabolic response of 3D endothelial microvessels to TNFα, including pro- and anti-inflammatory markers. We cultured 96 perfused microvessels against extracellular matrix (ECM) using the microvessels-on-a-chip platform technology recently developed by using the OrganoPlate platform of MIMETAS (<xref ref-type="bibr" rid="bib49">Wevers et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">van Duinen et al., 2017</xref>). The microchannels in the OrganoPlate were coated with gelatin, preventing endothelial cells from growing on glass and enabling them to form stable microvesseels. The shear stress in the microvessels, calculated based on a previous work, ranges from 1 to 5 dyne/cm<sup>2</sup> (<xref ref-type="bibr" rid="bib45">van Duinen et al., 2017</xref>). In vivo, the shear stress ranges from 95.5 dyne/cm<sup>2</sup> at the smallest capillaries to 2.8 dyne/cm<sup>2</sup> at the postcapillary venules (<xref ref-type="bibr" rid="bib20">Koutsiaris et al., 2007</xref>). Conditioned medium perfused through TNFα treated and control (untreated) microvessels was sampled, pooled and measured with a UPLC-MS/MS metabolomics method developed recently by us to study inflammation and oxidative stress (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib37">Schoeman et al., 2018</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Metabolomics workflow.</title><p>(<bold>a</bold>) Schematic diagram of the OrganoPlate 2-lane design and 3D reconstruction of the microvessels-on-a-chip formed by cultured HUVECs (blue: Hoechst, red: F-actin and green: VE-cadherin). All dimensions are in µm. (<bold>b</bold>) Collection of culture media after perfusion. The medium of four microvessels were pooled to form one sample. (<bold>c</bold>) Identification and quantification of prostaglandins, isoprostanes, lysophosphatidic acid (LPA) classes, sphingolipids and platelet activating factor (PAF) in microvessels-on-a-chip by UPLC-MS/MS using two different solvent gradients. (<bold>d</bold>) Pathway analysis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54754-fig1-v2.tif"/></fig><p>As a metabolic read-out for TNFα signaling, we measured prostaglandins, isoprostanes, LPAs, lysosphingolipids and PAF and first assessed the concentrations of these metabolites in the basic EGM2 medium and compared their concentrations after 18 hr incubation to condition the medium in the microvessels-on-a-chip cultures. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the peaks detected demonstrated that, while members of the prostaglandins and isoprostanes clearly increased after conditioning of the medium, most of the LPA metabolites were readily detectable in the medium and actually displayed a significant decreased concentration. When the EGM2 medium was incubated for 18 hr without exposure to the microvessels no significant changes in the concentrations of these metabolites was observed. Therefore, we conclude that during the conditioning of the medium, prostaglandins and isoprostanoids are excreted from the endothelial cells and that the LPA metabolites are consumed or actively degraded by the cells.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The peak area ratio of metabolites in the culture medium (EGM2) normalized with the peak area ratio of metabolites found in the culture medium after perfusion in the microvessels-on-a-chip for 18 hr (EGM2 HUVECs).</title><p>The peak area ratio is the peak area of the metabolites divided by the appropriate peak area of the internal standards. Fold changes below the 1 (blue) and above the 1 (red) indicates that low and high concentrations of fatty acids were present in medium before exposure to the microvessels. The data represent one biological replicate; n = 3 technical replicates.</p><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Peak area ratios of the identified metabolites in culture medium (EGM2) and in culture medium after perfusion in the microvessels-on-a-chip (EGM2 HUVECs).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54754-table1-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Bioactive lipid*</th><th valign="bottom">EGM2/EGM2 HUVECs</th><th valign="bottom">Bioactive lipid*</th><th valign="bottom">EGM2/EGM2 HUVECs</th></tr></thead><tbody><tr><td valign="bottom">PGF2α</td><td style="author-callout-style-b1" valign="bottom">0.1</td><td valign="bottom">LPA C22:5</td><td style="author-callout-style-b6" valign="bottom">18.2</td></tr><tr><td valign="bottom">PGF3α</td><td style="author-callout-style-b6" valign="bottom">2.1</td><td valign="bottom">LPA C16:0</td><td style="author-callout-style-b6" valign="bottom">21.3</td></tr><tr><td valign="bottom">8-iso-13, 14-dihydro-PGF2α</td><td style="author-callout-style-b1" valign="bottom">0.0</td><td valign="bottom">LPA C18:1</td><td style="author-callout-style-b6" valign="bottom">48.4</td></tr><tr><td valign="bottom">8-iso-PGF2α</td><td style="author-callout-style-b1" valign="bottom">0.2</td><td valign="bottom">LPA C22:4</td><td style="author-callout-style-b6" valign="bottom">5.9</td></tr><tr><td valign="bottom">5-iPF2α</td><td style="author-callout-style-b1" valign="bottom">0.4</td><td valign="bottom">cLPA C20:4</td><td style="author-callout-style-b6" valign="bottom">78.6</td></tr><tr><td valign="bottom">8, 12-iPF2α IV</td><td style="author-callout-style-b1" valign="bottom">0.5</td><td valign="bottom">LPA C18:0</td><td style="author-callout-style-b1" valign="bottom">0.0</td></tr><tr><td valign="bottom">LPA C14:0</td><td style="author-callout-style-b6" valign="bottom">6.2</td><td valign="bottom">cLPA C18:2</td><td style="author-callout-style-b1" valign="bottom">0.0</td></tr><tr><td valign="bottom">LPA C16:1</td><td style="author-callout-style-b6" valign="bottom">25.4</td><td valign="bottom">cLPA C16:0</td><td style="author-callout-style-b6" valign="bottom">14.8</td></tr><tr><td valign="bottom">LPA C22:6</td><td style="author-callout-style-b6" valign="bottom">17.7</td><td valign="bottom">cLPA C18:1</td><td style="author-callout-style-b6" valign="bottom">25.8</td></tr><tr><td valign="bottom">LPA C18:2</td><td style="author-callout-style-b6" valign="bottom">77.2</td><td valign="bottom">cLPA C18:0</td><td style="author-callout-style-b6" valign="bottom">11.1</td></tr><tr><td valign="bottom">LPA C20:4</td><td style="author-callout-style-b6" valign="bottom">31.0</td><td valign="bottom">S-1-P C18:1</td><td style="author-callout-style-b1" valign="bottom">0.9</td></tr></tbody></table><table-wrap-foot><fn><p>* The rest of the metabolites shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> are not displayed, because they were not detected in the EGM2.</p></fn></table-wrap-foot></table-wrap><p>When we assessed the biolipid composition of the conditioned medium of TNFα stimulated microvessels, 33 measured metabolites passed the quality control (QC) thresholds. <xref ref-type="fig" rid="fig2">Figure 2</xref> shows examples of the chromatograms of prostaglandin E2 and different isoprostanes isomers that were secreted by the microvessels after exposure to TNFα for 18 hr compared to the control samples showing a marked increase in abundance of a number of these metabolites. The control samples are microvessels without exposure to TNFα. Bar plots of the absolute concentrations of prostaglandins are presented in <xref ref-type="fig" rid="fig3">Figure 3a</xref>, showing a significant difference between untreated and TNFα treated microvessels. While at physiological concentration of TNFα (0.4 ng/ml) there was an increase in the excretion of PGF1α, PGF2α, PGF3α, PGE2, PGD2 and 13, 14-dihydro-PGF2α, however, no significant difference between the untreated and TNFα treated microvessels was evident, except for PGF1α. At 15 ng/ml a stronger differential response was observed for selected isoprostanes, several LPAs, sphingolipids and PAF (<xref ref-type="fig" rid="fig3">Figure 3b–e</xref>). The relative concentrations of the bioactive lipids found in the microvessels-on-a-chip are strikingly similar with those found in normal human blood vessels (<xref ref-type="table" rid="table2">Table 2</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Inflammatory and oxidative stress markers in microvessels-on-a-chip.</title><p>Reconstructed LC-MS/MS ion chromatograms of PGE2, 5-iPF2α IV, iPF2α and 8, 12-iPF2α IV in microvessels treated with 50 ng/ml TNFα for 18 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54754-fig2-v2.tif"/></fig><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TNFα-induced concentration profile changes of the signaling lipids in the microvessels-on-a-chip.</title><p>Concentrations of (<bold>a</bold>) prostaglandins, (<bold>b</bold>) isoprostanes, (<bold>c</bold>) lysophosphatidic acid (LPA) classes, (<bold>d</bold>) sphingolipids and (<bold>e</bold>) platelet activating factor (PAF) with available standards detected in the microvessels without TNFα exposure (control) and after exposure to 0.4 and 15 ng/ml TNFα for 18 hr. Data represent mean and s.e.m. of three biological replicates per condition; n = 4–6 technical replicates. Significance determined by unpaired Student’s t-test; *p&lt;0.1, **p&lt;0.05, ***p&lt;0.01, ****p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54754-fig3-v2.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Comparison of the concentration of bioactive lipids between living human blood vessel and human microvessels-on-a- chip.</title><p>The concentrations in human blood vessel were obtained from HMDB (<xref ref-type="bibr" rid="bib53">Wishart et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Wishart et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Wishart et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Wishart et al., 2009</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th colspan="2" valign="bottom">Human blood vessel</th><th colspan="2" valign="bottom">Microvessels-on-a-chip</th></tr><tr><th valign="bottom">Bioactive lipid</th><th valign="bottom">Healthy</th><th valign="bottom">Diseased</th><th valign="bottom">Healthy</th><th valign="bottom">Diseased</th></tr></thead><tbody><tr><td valign="bottom">PGF1α</td><td valign="bottom">∼0.0317–0.376 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.350 nM</td><td valign="bottom">∼0.527–1.412 nM</td></tr><tr><td valign="bottom">PGF2α</td><td valign="bottom">∼0.144–0.371 nM</td><td valign="bottom">∼0.4–1.6 nM</td><td valign="bottom">∼3.96 nM</td><td valign="bottom">∼5.36–12.5 nM</td></tr><tr><td valign="bottom">PGE2*</td><td valign="bottom">∼0.13–0.172 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.175 nM</td><td valign="bottom">∼0.194–0.281 nM</td></tr><tr><td valign="bottom">PGE1</td><td valign="bottom">&lt;0.1 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.0225 nM</td><td valign="bottom">∼0.0246–0.0308 nM</td></tr><tr><td valign="bottom">PGD2</td><td valign="bottom">∼0.065–0.2 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.254 nM</td><td valign="bottom">∼0.257–0.336 nM</td></tr><tr><td valign="bottom">PGA2</td><td valign="bottom">∼0.0448–0.496 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.006 nM</td><td valign="bottom">∼0.0048–0.0058 nM</td></tr><tr><td valign="bottom">8-iso-PGF2α</td><td valign="bottom">∼0.057–0.57 nM</td><td valign="bottom">-</td><td valign="bottom">∼0.103 nM</td><td valign="bottom">∼0.122–0.216 nM</td></tr><tr><td valign="bottom">S-1-P C18:1</td><td valign="bottom">∼0.5–3.0 nM</td><td valign="bottom">-</td><td valign="bottom">∼2.12 nM</td><td valign="bottom">∼1.47–2.11 nM</td></tr><tr><td valign="bottom">Sph C18:1</td><td valign="bottom">∼1.3–50 nM</td><td valign="bottom">-</td><td valign="bottom">∼44.2 nM</td><td valign="bottom">∼45.2–49.8 nM</td></tr><tr><td valign="bottom">Spha C18:0</td><td valign="bottom">∼1.3–50 nM</td><td valign="bottom">-</td><td valign="bottom">∼6.0 nM</td><td valign="bottom">∼6.2–6.7 nM</td></tr></tbody></table></table-wrap><p>Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C (PKC), hence of NFκB, that relates to TNFα signaling and causes a wide range of effects in cells. As it is a known and potent up-regulator of cyclooxygenase-2 (COX-2) (<xref ref-type="bibr" rid="bib8">Chang et al., 2005</xref>), we next measured the effect of PMA on the secretion of the biolipids to compare the TNFα response to a condition of maximal stimulation. When our combined results were plotted in a heatmap, marked differences are observed between control- and TNFα or PMA-treated microvessels (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Heatmap of prostaglandins, isoprostanes, lysophosphatidic acid (LPA) classes, sphingolipids and platelet activating factor (PAF) detected in the microvessels-on-a-chip.</title><p>The fold changes were measured with respect to the controls and log2 transformed. The controls are microvessels unexposed to TNFα and PMA. The metabolites are characterized by their inflammatory action (anti- or pro-inflammatory), platelet activation (anti- or pro-platelet activation), vascular tone (constriction or dilation) and angiogenic action (anti- or pro-angiogenic). The data were obtained from the experiments done in <xref ref-type="fig" rid="fig3">Figure 3</xref> with three biological replicates per condition; n = 4–6 technical replicates.</p><p><supplementary-material id="table3sdata1"><label>Table 3—source data 1.</label><caption><title>Concentrations of the identified metabolites in the microvessels-on-a-chip.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54754-table3-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th valign="bottom"/><th colspan="3" valign="bottom">Fold change of concentration</th><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/></tr><tr><th valign="bottom"/><th valign="bottom">Bioactive lipid</th><th valign="bottom">15 ng/ml</th><th valign="bottom">50 ng/ml</th><th valign="bottom">20 ng/ml</th><th valign="bottom">Inflammatory</th><th valign="bottom">Platelet</th><th valign="bottom">Vascular</th><th valign="bottom">Angiogenic</th></tr></thead><tbody><tr><td valign="bottom"/><td valign="bottom"/><td valign="bottom">TNF</td><td valign="bottom">TNF</td><td valign="bottom">PMA</td><td valign="bottom">action</td><td valign="bottom">activation</td><td valign="bottom">tone</td><td valign="bottom">action</td></tr><tr><td rowspan="8">Prostaglandins</td><td valign="bottom">PGF1α</td><td style="author-callout-style-b6" valign="bottom">2.0</td><td style="author-callout-style-b6" valign="bottom">1.8</td><td style="author-callout-style-b6" valign="bottom">5.0</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom">con</td><td valign="bottom"/></tr><tr><td valign="bottom">PGF2α</td><td style="author-callout-style-b6" valign="bottom">1.7</td><td style="author-callout-style-b6" valign="bottom">1.5</td><td style="author-callout-style-b6" valign="bottom">5.0</td><td valign="bottom">pro</td><td valign="bottom">no</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PGF3α</td><td style="author-callout-style-b6" valign="bottom">1.5</td><td style="author-callout-style-b6" valign="bottom">1.1</td><td style="author-callout-style-b6" valign="bottom">4.4</td><td valign="bottom">anti</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">PGE2*</td><td valign="bottom">0.7</td><td valign="bottom">0.7</td><td style="author-callout-style-b6" valign="bottom">.7</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">dil</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PGE1</td><td valign="bottom">0.5</td><td valign="bottom">0.4</td><td style="author-callout-style-b6" valign="bottom">2.7</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">dil</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PGD2</td><td valign="bottom">0.4</td><td style="author-callout-style-b6" valign="bottom">3.4</td><td style="author-callout-style-b6" valign="bottom">3.5</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">13, 14-dihydro-PGF2α</td><td valign="bottom">0.7</td><td valign="bottom">0.5</td><td style="author-callout-style-b6" valign="bottom">2.3</td><td valign="bottom">pro</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">PGA2</td><td valign="bottom">−0.3</td><td valign="bottom">0.0</td><td style="author-callout-style-b6" valign="bottom">2.6</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td rowspan="6">Isoprostanes</td><td valign="bottom">8-iso-13, 14-dihydro-PGF2α</td><td style="author-callout-style-b6" valign="bottom">1.4</td><td style="author-callout-style-b6" valign="bottom">1.3</td><td style="author-callout-style-b6" valign="bottom">4.6</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom">anti</td></tr><tr><td valign="bottom">8-iso-PGF2α*</td><td style="author-callout-style-b6" valign="bottom">1.1</td><td valign="bottom">0.9</td><td style="author-callout-style-b6" valign="bottom">4.2</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">8-iso-PGE2</td><td valign="bottom">0.1</td><td valign="bottom">0.0</td><td style="author-callout-style-b6" valign="bottom">2.1</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">8-iso-PGE1</td><td valign="bottom">0.1</td><td valign="bottom">0.0</td><td valign="bottom">0.7</td><td valign="bottom"/><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">5-iPF2α</td><td valign="bottom">0.0</td><td valign="bottom">0.0</td><td valign="bottom">0.0</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">8, 12-iPF2α IV</td><td valign="bottom">−0.1</td><td valign="bottom">0.0</td><td valign="bottom">0.2</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td rowspan="12">Lysophosphatidic acids</td><td valign="bottom">LPA C14:0</td><td valign="bottom">−0.2</td><td valign="bottom">−0.2</td><td valign="bottom">−0.4</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C16:1</td><td valign="bottom">−0.4</td><td valign="bottom">−0.3</td><td valign="bottom">−0.6</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C22:6*</td><td valign="bottom">0.4</td><td valign="bottom">0.5</td><td valign="bottom">0.2</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C18:2</td><td valign="bottom">0.1</td><td valign="bottom">0.0</td><td valign="bottom">−0.1</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C20:4</td><td valign="bottom">0.3</td><td valign="bottom">0.4</td><td valign="bottom">0.3</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C22:5*</td><td valign="bottom">0.5</td><td valign="bottom">0.6</td><td valign="bottom">0.3</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C16:0</td><td valign="bottom">−0.2</td><td valign="bottom">−0.3</td><td valign="bottom">−0.3</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C18:1</td><td valign="bottom">0.1</td><td valign="bottom">0.2</td><td valign="bottom">−0.1</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">cLPA C20:4</td><td valign="bottom">−0.1</td><td valign="bottom">−0.2</td><td valign="bottom">−0.1</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">LPA C18:0</td><td valign="bottom">0.1</td><td valign="bottom">0.0</td><td valign="bottom">−0.2</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">cLPA C16:0</td><td valign="bottom">−0.2</td><td valign="bottom">0.0</td><td valign="bottom">0.0</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C18:0</td><td valign="bottom">−0.2</td><td valign="bottom">−0.1</td><td valign="bottom">−0.2</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td rowspan="3">Sphingolipids</td><td valign="bottom">S-1-P C18:1</td><td valign="bottom">−0.5</td><td valign="bottom">−0.6</td><td valign="bottom">−0.9</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">Sph C18:1</td><td valign="bottom">0.2</td><td valign="bottom">0.1</td><td valign="bottom">0.0</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">Spha C18:0</td><td valign="bottom">0.2</td><td valign="bottom">0.0</td><td valign="bottom">−0.1</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom"/><td valign="bottom">PAF C16:0</td><td valign="bottom">−0.2</td><td valign="bottom">−0.2</td><td valign="bottom">−0.4</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr></tbody></table><table-wrap-foot><fn><p>* Validated markers of oxidative stress.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Impact of TNFα on prostaglandin levels</title><p>As shown in <xref ref-type="table" rid="table3">Table 3</xref>, overnight exposure to TNFα and PMA shows increase in the release of the prostaglandins PGF1α, PGF2α, PGF3α, PGE2, PGD2 and 13, 14-dihydro-PGF2α from the TNFα treated microvessels (<xref ref-type="fig" rid="fig3">Figure 3a</xref> and <xref ref-type="table" rid="table3">Table 3</xref>). During inflammation, ROS contributes to the increased PGE2, PGF2α, PGD2 and 13, 14-dihydro-PGF2α production through the release of arachidonic acid and COX-2 activation, having a pro-inflammatory effect in the endothelium (<xref ref-type="bibr" rid="bib54">Wong and Vanhoutte, 2010</xref>; <xref ref-type="bibr" rid="bib11">Dworski et al., 2001</xref>). At the same time, anti-inflammatory prostaglandins PGF1α, PGF3α, PGE1, and PGA2 are also secreted by the endothelium (<xref ref-type="bibr" rid="bib43">Trebatická et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Gezginci-Oktayoglu et al., 2016</xref>). PGE1 and PGA2 are known to suppress TNFα induced NFκB activation and production of ROS (<xref ref-type="bibr" rid="bib28">Ohmura et al., 2017</xref>). Relating to these two prostaglandins, no differences were detected in our system between untreated and TNFα treated microvessels for 18 hr.</p></sec><sec id="s2-3"><title>Impact of TNFα on isoprostane levels</title><p>When we focus on the compounds produced by the reaction of free radicals with arachidonic acid, the isoprostanes, high levels of 8-iso-13, 14-dihydro-PGF2α and 8-iso-PGF2α were detected in the supernatant of TNFα treated microvessels (<xref ref-type="fig" rid="fig3">Figure 3b</xref> and <xref ref-type="table" rid="table3">Table 3</xref>). These metabolites inhibit platelet aggregation and induce monocyte adhesion to endothelial cells (<xref ref-type="bibr" rid="bib35">Rokach et al., 1997</xref>; <xref ref-type="bibr" rid="bib10">Duracková, 2010</xref>). We also detected 8-iso-PGE2, 5-iPF2α, 8, 12-iPF2α IV and 8-iso-PGE1 in the control sample and TNFα induced microvessels. 8-iso-PGE1 is recognized as vasoconstrictor with a similar effect as PGF2α (<xref ref-type="bibr" rid="bib26">Nakano and Kessinger, 1970</xref>). However, no significant difference between the two groups was evident after incubating the microvessels for 18 hr with TNFα.</p></sec><sec id="s2-4"><title>Impact of TNFα on lysophosphatidic acids, sphingolipids and platelet activating factor</title><p>Looking at lipids that mediate diverse biological actions, the LPA classes, sphingosine and PAF are appropriate markers to take along in our metabolic read-out, because of their diverse biological actions. The LPA classes consist of LPAs and cyclic-lysophosphatidic acids (cLPAs). They are formed by activated platelets and oxidation of low-density lipoproteins (LDLs) (<xref ref-type="bibr" rid="bib18">Karshovska et al., 2018</xref>). Once an inflammatory response is triggered, LPAs can activate platelets (<xref ref-type="bibr" rid="bib19">Khandoga et al., 2008</xref>) and lead to endothelial dysfunction by activating NFκB (<xref ref-type="bibr" rid="bib5">Biermann et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Yang et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Ninou et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Palmetshofer et al., 1999</xref>). On the other hand, cLPAs inhibit pro-inflammatory cytokine expression in the endothelium (<xref ref-type="bibr" rid="bib44">Tsukahara et al., 2014</xref>). In our data, we saw high concentrations of several LPAs in the control sample compared to TNFα treated microvessels. Similar results were seen in the levels of sphingosine-1-phosphate (S-1-P) and PAF (<xref ref-type="table" rid="table3">Table 3</xref> and <xref ref-type="fig" rid="fig3">Figure 3c–e</xref>). In TNFα signaling, S-1-P binds to TNF receptor-associated factor 2 (TRAF2) to activate NFκB, while PAF induces vascular permeability (<xref ref-type="bibr" rid="bib2">Alvarez et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Palur Ramakrishnan et al., 2017</xref>).</p></sec><sec id="s2-5"><title>TNFα induced bioactive lipid profiles from endothelial cells in 3D configuration are less inflammatory compared to 2D monolayers</title><p>To assess whether these three-dimensional microvessels display a more anti-inflammatory phenotype, we compared the bioactive lipid response of the 3D microvessels-on-a-chip to TNFα to that of 2D endothelial cell monolayers. In addition, we made a detailed inventory of the reported action of the individual lipids on inflammation, platelet activation, vascular tone and angiogenesis (for references see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). When the TNFα-induced biolipids profiles are listed in relation to their biological activities (<xref ref-type="table" rid="table4">Table 4</xref>), we conclude that the 3D microvessels-on-a-chip display a more dynamic, less inflammatory response to TNFα, that resembles more the human situation, compared to classical 2D endothelial cell cultures. In particular, the anti-inflammatory prostaglandins PGF1α, PGF3α, and PGD2 are increased to a larger extent and the anti-inflammatory lysophosphatidic acids are maintained or decreased to a lesser extent. In concert, the pro-inflammatory lipids PGE2, 8-iso-PGE2 and 8-iso-PGF2α are present at higher levels in the medium of the TNFα exposed 2D endothelial monolayer culture. The elevated levels of the oxidative stress markers PGE2, 8-iso-PGF2α (<xref ref-type="bibr" rid="bib34">Ridker, 2004</xref>), LPA C22:5 and LPA C22:6 (<xref ref-type="bibr" rid="bib1">Ackerman et al., 2016</xref>) confirm the increased inflammatory status of the 2D cultures making it tempting to speculate that an increased production of ROS in these cells may underlie these responses. The response of the microvasculature to inflammatory cytokines such as TNFα is often directly associated with inhibition of platelet activation (to maintain patency of the microvessel), a vasoconstrictive response and a pro-angiogenic response characterized by the loss of endothelial cell-cell contacts and microvascular leakage. Many of these activities are also driven by the bioactive lipids in our panel (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), and it is interesting to note that concomitantly to the less inflammatory nature of the profiles of the conditioned media derived from the 3D microvessel the profile also suggests to be more restrictive of platelet activation, less vasoconstrictive and less angiogenic. It should be noted that we did not compare the excretion of bioactive of unstimulated 2D cell cultures and 3D vessels as the normalization on the number of endothelial cells would not have been straightforward.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Heatmap of pro- and anti- inflammatory and oxidative stress markers measured in 3D microvessels-on-a-chip and 2D endothelial cell monolayers.</title><p>The cells were treated with 15 ng/ml TNFα in the same experiment as <xref ref-type="fig" rid="fig3">Figure 3</xref>. The fold changes were measured with respect to the controls and log2 transformed. The controls are microvessels unexposed to TNFα and PMA. The metabolites are characterized by their inflammatory action (anti- or pro-inflammatory), platelet activation (anti- or pro-platelet activation), vascular tone (constriction or dilation) and angiogenic action (anti- or pro-angiogenic). The data represent one biological replicate; n = 2–3 technical replicates.</p><p><supplementary-material id="table4sdata1"><label>Table 4—source data 1.</label><caption><title>Peak area ratios of the identified metabolites in 6-well plates and in the microvessels-on-a-chip.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54754-table4-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th colspan="2" valign="bottom">Fold change of</th><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/></tr><tr><th valign="bottom"/><th colspan="2" valign="bottom">Concentration</th><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/><th valign="bottom"/></tr></thead><tbody><tr><td valign="bottom">Bioactive lipid</td><td valign="bottom">2D</td><td valign="bottom">3D</td><td valign="bottom">Inflammatory</td><td valign="bottom">Platelet</td><td valign="bottom">Vascular</td><td valign="bottom">Angiogenic</td></tr><tr><td valign="bottom"/><td valign="bottom">TNF</td><td valign="bottom">TNF</td><td valign="bottom">action</td><td valign="bottom">activation</td><td valign="bottom">tone</td><td valign="bottom">action</td></tr><tr><td valign="bottom">PGF1α</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td style="author-callout-style-b6" valign="bottom">3.4</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom">con</td><td valign="bottom"/></tr><tr><td valign="bottom">PGF3α</td><td style="author-callout-style-b6" valign="bottom">1.0</td><td style="author-callout-style-b6" valign="bottom">6.6</td><td valign="bottom">anti</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">PGE1</td><td style="author-callout-style-b6" valign="bottom">2.1</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">dil</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PGD2</td><td style="author-callout-style-b6" valign="bottom">2.3</td><td style="author-callout-style-b6" valign="bottom">6.5</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">PGA2</td><td valign="bottom">0.7</td><td valign="bottom">0.0</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C20:4</td><td valign="bottom">−0.7</td><td valign="bottom">−0.5</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C18:2</td><td valign="bottom">−0.5</td><td valign="bottom">0.0</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C16:0</td><td valign="bottom">−0.6</td><td valign="bottom">−0.3</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C18:1</td><td valign="bottom">−0.9</td><td valign="bottom">−0.2</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">cLPA C18:0</td><td valign="bottom">−0.6</td><td valign="bottom">−0.2</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">no</td><td valign="bottom"/></tr><tr><td valign="bottom">S-1-P C18:1</td><td style="author-callout-style-b1" valign="bottom">−2.0</td><td valign="bottom">−0.9</td><td valign="bottom">anti</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">8-iso-PGE1</td><td style="author-callout-style-b6" valign="bottom">1.8</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td valign="bottom"/><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">5-iPF2α</td><td valign="bottom">0.3</td><td valign="bottom">−0.1</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">PGF2α</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td style="author-callout-style-b6" valign="bottom">2.2</td><td valign="bottom">pro</td><td valign="bottom">no</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PGE2*</td><td style="author-callout-style-b6" valign="bottom">2.4</td><td style="author-callout-style-b6" valign="bottom">1.0</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">dil</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">13, 14-dihydro-PGF2α</td><td valign="bottom">0.9</td><td style="author-callout-style-b6" valign="bottom">1.1</td><td valign="bottom">pro</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">8-iso-13, 14-dihydro-PGF2α</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td style="author-callout-style-b6" valign="bottom">1.9</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom">anti</td></tr><tr><td valign="bottom">8-iso-PGF2α*</td><td style="author-callout-style-b6" valign="bottom">2.0</td><td style="author-callout-style-b6" valign="bottom">1.3</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">8-iso-PGE2</td><td valign="bottom">0.6</td><td valign="bottom">−0.3</td><td valign="bottom">pro</td><td valign="bottom">anti</td><td valign="bottom">con</td><td valign="bottom">anti</td></tr><tr><td valign="bottom">LPA C14:0</td><td valign="bottom">0.0</td><td valign="bottom">−0.8</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C16:1</td><td style="author-callout-style-b1" valign="bottom">−1.0</td><td style="author-callout-style-b1" valign="bottom">−1.0</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C22:6*</td><td valign="bottom">0.0</td><td valign="bottom">−0.3</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C18:2</td><td style="author-callout-style-b1" valign="bottom">−1.0</td><td style="author-callout-style-b1" valign="bottom">−1.2</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C20:4</td><td valign="bottom">−0.2</td><td valign="bottom">−0.4</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C22:5*</td><td style="author-callout-style-b6" valign="bottom">1.0</td><td valign="bottom">−0.1</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C16:0</td><td valign="bottom">−0.6</td><td valign="bottom">−0.6</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C18:1</td><td valign="bottom">−0.5</td><td style="author-callout-style-b1" valign="bottom">−1.0</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">LPA C18:0</td><td valign="bottom">0.1</td><td valign="bottom">−0.9</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr><tr><td valign="bottom">PAF C16:0</td><td valign="bottom">−0.5</td><td valign="bottom">−0.8</td><td valign="bottom">pro</td><td valign="bottom">pro</td><td valign="bottom">con</td><td valign="bottom">pro</td></tr></tbody></table><table-wrap-foot><fn><p>* Validated markers of oxidative stress.</p></fn></table-wrap-foot></table-wrap><p>The observed differences between the 2D and the 3D chip-based platforms may be attributed to the mechanical properties of the two systems (<xref ref-type="bibr" rid="bib21">Lee et al., 2009</xref>). The microvessels-on-a-chip are surrounded by an ECM layer and the 3D configuration allows intensified cell-cell interactions, resembling the in vivo situation. Moreover, vascular endothelial cells in vivo are influenced by distinct hemodynamic forces and this applies also to the endothelial cells in our microvessels-on-a-chip. Evidence suggest that shear stress activates phospholipids turnover that is involved in the production of free arachidonic acid (<xref ref-type="bibr" rid="bib4">Bhagyalakshmi et al., 1992</xref>). This might also explain the differences we see between the increase/decrease of fatty acids in the microvessels-on-a-chip and the 2D cell culture. As shear stress influences RhoA activity and stress fiber formation, the regulation of fatty acids, RhoA might be important in this process (<xref ref-type="bibr" rid="bib22">Liu et al., 2014</xref>). In addition, the environmental changes in the 3D configuration could impact on the expression of the TNF receptors.</p><p>Several reports showed that oxidative stress induces endothelial dysfunction, which plays a central role in vascular diseases. It can promote the expression of pro-inflammatory and pro-coagulant factors, apoptosis and impair the release of nitric oxide (<xref ref-type="bibr" rid="bib38">Schulz et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Shiraki et al., 2012</xref>). This study set out with the aim of using metabolomics as a readout of endothelial function in microvessels-on-a-chip exposed to TNFα, to trigger inflammatory responses seen in vasculopathy. For the first time we show that the regulation of prostaglandins, isoprostanes, LPAs, sphingolipids and PAF can be measured in our microfluidic system, even though they cause profound physiological effects at very dilute concentrations that serve as early-stage markers of oxidative stress and inflammation (<xref ref-type="bibr" rid="bib36">Ryu et al., 2015</xref>). The findings support the model that TNFα signaling induces ROS production that causes changes in signal transduction and gene expression, which leads to release of oxidative stress and inflammatory markers (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Further research should be undertaken to confirm the results in gene and protein levels.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TNFα induces the release of oxidative stress and inflammatory markers in endothelial cells.</title><p>Exposure to TNFα, causes TNF signaling in the microvessels to produce ROS from endogenous sources: mitochondria, xanthine oxidase, NADPH oxidase and uncoupled eNOS. Sphingosine-1-phosphate (S-1-P) is needed in order for TNF receptor-associated factor 2 (TRAF2) to form a complex with the TNF receptor 1 (TNFR1). These lead to the conversion of arachidonic acid (AA) to isoprostanes and NFκB activation. Moreover, AA is enzymatically converted by cyclooxygenase-2 (COX-2) to prostaglandins (PGs). At the same time, autotaxin (ATX) and phospholipase A<sub>2</sub> (PLA<sub>2</sub>) are upregulated, resulting in the syntheses of lysophosphatidic acid (LPA) classes and platelet activating factor (PAF). Through their receptors, LPAs and PAF further promote the activation of COX-2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54754-fig4-v2.tif"/></fig></sec><sec id="s2-6"><title>Conclusions</title><p>We demonstrate bioactive lipid profiles can be readily detected from minor volumes of &lt;1 µl of conditioned medium from microvessels-on-a-chip and display a more dynamic, less inflammatory response to TNFα compared to classical two-dimensional endothelial cell cultures. We can conclude that the response to TNFα resembles for the microvessels-on-a-chip more the human situation as described in the literature than the 2D endothelial cell culture. As the physiological readout of endothelial function is a critical aspect in using microvessels-on-a-chip for disease and drug research, the results suggest that the metabolic readout using metabolomics is more informative compared to morphological changes studied with imaging analyses of phenotypic changes. But it is the combination of both techniques, metabolic readout using metabolomics and imaging analysis that may facilitate mechanistic studies and the detection and validation of biomarkers for microvascular disease at the systemic level. Furthermore, it will provide the information needed to understand microvascular destabilization and will generate a knowledge base for developing and testing personalized therapeutic interventions.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Biological sample (Human)</td><td>primary human umbilical vein endothelial cells</td><td>Leiden University Medical Center (LUMC)</td><td/><td>freshly isolated from umbilical cord of male newborns</td></tr><tr><td>Chemical compound, drug</td><td>phorbol 12-myristate 13-acetate</td><td>Sigma-Aldrich</td><td>Cat#:P8139</td><td/></tr><tr><td>Peptide, <break/>recombinant protein</td><td>tumor necrosis factor-α</td><td>Sigma-Aldrich</td><td>Cat#:H8916</td><td/></tr><tr><td>Biological sample (Rat)</td><td>rat tail collagen type 1</td><td>Trevigen</td><td>Cat#:3440-005-01</td><td/></tr><tr><td>Antibody</td><td>mouse anti-human CD144</td><td>BD Biosciences</td><td>Cat#:555661; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_396015">AB_396015</ext-link></td><td>IF(1:150)</td></tr><tr><td>Antibody</td><td>sheep anti-human CD31</td><td>R and D Systems</td><td>Cat#:AF806; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_355617">AB_355617</ext-link></td><td>IF(1:150)</td></tr><tr><td>Antibody</td><td>rabbit anti-human vWF</td><td>Agilent Dako</td><td>Cat#:A0082; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2315602">AB_2315602</ext-link></td><td>IF(1:1000)</td></tr><tr><td>Antibody</td><td>alexa fluor 488-conjugated goat anti-mouse</td><td>ThermoFisher</td><td>Cat#:R37120; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2556548">AB_2556548</ext-link></td><td>IF(1:250)</td></tr><tr><td>Antibody</td><td>alexa fluor 488-conjugated donkey anti-sheep</td><td>ThermoFisher</td><td>Cat#:A11015; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_141362">AB_141362</ext-link></td><td>IF(1:250)</td></tr><tr><td>Antibody</td><td>alexa fluor 647-conjugated goat anti-rabbit</td><td>ThermoFisher</td><td>Cat#:A27040; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2536101">AB_2536101</ext-link></td><td>IF(1:250)</td></tr><tr><td>Other</td><td>rhodamine phalloidin</td><td>Sigma-Aldrich</td><td>Cat#:P1951; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2315148">AB_2315148</ext-link></td><td>IF(1:200)</td></tr><tr><td>Other</td><td>hoechst</td><td>Invitrogen</td><td>Cat#:H3569; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2651133">AB_2651133</ext-link></td><td>IF(1:2000)</td></tr><tr><td>Software, algorithm</td><td>LabSolutions</td><td>Shimadzu</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_018241">SCR_018241</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>SPSS</td><td>SPSS</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002865">SCR_002865</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism</td><td>GraphPad</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr></tbody></table></table-wrap><sec id="s3-1"><title>Cell culture</title><p>Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cord of newborns, collected with informed consent, by an adaption of the method developed by <xref ref-type="bibr" rid="bib17">Jaffe et al., 1973</xref>. Although denoted as veins, umbilical veins carry oxygenated blood and thus the phenotype of their endothelium is similar to arterial endothelial cells.</p><p>The umbilical cord was severed from the placenta soon after birth and placed in a sterile container filled with phosphate-buffered saline (PBS; Fresenius Kabi, The Netherlands) and held at 4°C until processing. The cord was inspected and at both ends a piece of 1 cm was cut off to remove damaged tissue from clamping. Subsequently, the umbilical vein was cannulated and perfused with PBS to wash out the blood and allowed to drain. When clear fluid flow was observed, the vein was filled with trypsin/EDTA solution (CC-5012, Lonza, USA), placed in the container filled with PBS and incubated at 37°C for 20 min. After incubation, the trypsin-EDTA solution containing the endothelial cells was flushed from the cord with air and afterwards PBS. The effluent was collected in a sterile 50 ml tube containing 20 ml Endothelial Cell Growth Medium 2 (EGM2; C-39216, PromoCell, Germany) supplemented with antibiotics and the cell suspension was centrifuged at 1200 rpm for 7 min. The cell pellet was resuspended in 10 ml EGM2 and cultured on 1% gelatin-coated T75 flasks. Cells were maintained in a 37°C incubator with 5% CO<sub>2</sub> and the medium was refreshed every other day. After 80% confluency, cells were spilt at 1:3 ratio and cultured in new 1% gelatin-coated T75 flasks. The isolated cells were positive for the endothelial cell markers, including platelet endothelial cell adhesion molecule (PECAM-1) and von Willebrand factor (vWF) (<xref ref-type="fig" rid="fig5">Figure 5</xref>). All experiments using HUVECs were repeated six times using cells from three different male donors at passage 3.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Expression of platelet endothelial cell adhesion molecule (PECAM-1) and von Willebrand factor (vWF) in isolated human umbilical vein endothelial cells (HUVECs).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54754-fig5-v2.tif"/></fig><p>For 2D experiments, we cultured 50 ·10<sup>3</sup> cells/ml in 24-well plates overnight at 37°C in humidified air containing 5% CO<sub>2</sub>. The following day, the cells were incubated with 15 and 50 ng/ml TNFα (H8916, Sigma-Aldrich, The Netherlands) and 20 ng/ml phorbol 12-myristate 13-acetate (PMA; P8139, Sigma-Aldrich, The Netherlands) for 18 hr. The medium was collected and stored in −80°C.</p><p>We used the OrganoPlate (9603-400-B, MIMETAS, The Netherlands) for all microfluidic cell culture experiments. The microvascular and extracellular matrix (ECM) channels were separated by phaseguides (<xref ref-type="bibr" rid="bib48">Vulto et al., 2011</xref>). Before seeding the cells, 4 mg/ml rat tail collagen type 1 (3440-005-01, Trevigen, USA) neutralized with 10% 37 g/L Na<sub>2</sub>CO<sub>3</sub> (S5761, Sigma-Aldrich, The Netherlands) and 10% 1 M HEPES buffer (15630-056, Gibco, The Netherlands) was added in the ECM channels. Subsequently, the collagen was let to polymerize by incubating the device for 10 min in the incubator at 37°C and 5% CO<sub>2</sub>. The observation windows were filled with 50 µl Hank’s Balanced Salt Solution with calcium and magnesium buffers (HBSS+; 24020117, Life Technologies, The Netherlands) for optical clarity and to prevent gel dehydration. Using a repeater pipette, 2 µl of 1% gelatin was added into the inlet of each microvascular channel and the device was put in the incubator at 37°C for 30 min. We trypsinized cells at 80-90% confluency and seeded 15·10<sup>6</sup> cells/ml in the outlet of the microvascular channels of the OrganoPlate. Afterwards, the cells were incubated at 37°C and 5% CO<sub>2</sub> for one hour to allow microvascular formation. After incubation, 50 μl of culture medium was added to the inlets and outlets of the microvascular channels. The device was placed on a rocker platform with a 7° angle of motion and an eight-minute timed operation to allow continuous flow of minor volumes of medium in the microvessels. The microvascular channels typically contain volumes of &lt;1 µl. After 24 hours, the medium was refreshed, and the HUVECs were cultured for an additional 3-4 days. The microvessels were treated with TNFα (0.4, 15 and 50 ng/ml) and PMA (20 ng/ml) for 18 hours. Subsequently, medium of four microvessels were pooled to form one sample to allow analyses of metabolites at low concentrations due to low cell numbers. This still allowed us to create three biological replicates with 4 – 6 technical replicates data per experimental condition for metabolomics analyses. The samples were stored in -80°C.</p></sec><sec id="s3-2"><title>Immunofluorescence staining</title><p>For immunofluorescence staining, HUVECs were fixed using 4% paraformaldehyde (PFA) in HBSS+ for 10 min at room temperature. The fixative was aspirated, and the cells were rinsed once with HBSS+. Next, the cells were permeabilized for 2 min with 0.2% Triton X-100 in HBSS+ and washed once with HBSS+. The cells were blocked in 5% BSA in HBSS+ for 30 min and incubated with the primary antibody solution overnight at 4°C. Mouse anti-human CD144 (1:150; 555661, BD Biosciences, USA), sheep anti-human CD31 (1:150; AF806, R and D Systems, The Netherlands) and rabbit anti-human vWF (1:1000; A0082, Agilent Dako, USA) were used as the primary antibodies. The cells were washed with HBSS+, followed by an one-hour incubation with Hoechst (1:2000; H3569, Invitrogen, USA), rhodamine phalloidin (1:200; P1951, Sigma-Aldrich, The Netherlands) and the secondary antibody solution, containing Alexa Fluor 488-conjugated goat anti-mouse (1:250; R37120, ThermoFisher, USA), Alexa Fluor 488-conjugated donkey anti-sheep (1:250; A11015, ThermoFisher, USA) and Alexa Fluor 647-conjugated goat anti-rabbit (1:250; A27040, ThermoFisher, USA) antibodies. The cells were washed three times with HBSS+. High-quality Z-stack images of the stained cells were acquired using a high-content confocal microscope (Molecular Devices, ImageXpress Micro Confocal).</p></sec><sec id="s3-3"><title>Metabolic profiling</title><p>All samples were measured using an oxidative and nitrosative stress profiling platform which has been developed and validated in our lab (<xref ref-type="bibr" rid="bib37">Schoeman et al., 2018</xref>). This platform covers various isoprostane classes, signaling lipids from the sphingosine and sphinganine classes and their phosphorylated forms, as well as three classes of lysophosphatidic acids: lysophosphatidic acids, alkyl-lysophosphatidic acids and cyclic-lysophosphatidic acids (all ranging from C14 to C22 chain length species). For metabolite extraction, sample preparation procedure was according to the in-house experimental protocol which has been standardized and published; extra samples were pooled for internal quality control (QC) (<xref ref-type="bibr" rid="bib37">Schoeman et al., 2018</xref>). Briefly, cell media (150 μl) were thawed on ice and added with 5 μl antioxidant solution and 10 μl internal standards (ISTDs). Acidified with citric acid/phosphate buffer (pH 4.5), all samples were then dealt with liquid-liquid extraction (LLE) with 1 mL of butanol and ethyl acetate (1:1 v/v). Samples were vortexed and centrifuged and then the organic phase was collected and dried. After reconstitution with ice-cold 70% MeOH injection solution, each sample was again vortexed and centrifuged and the supernatant was transferred to the insert in a glass vial. Ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) based analysis was then applied for low-pH measurement (Shimadzu LCMS-8060, Japan) and high-pH measurement (Shimadzu LCMS-8050, Japan) respectively.</p></sec><sec id="s3-4"><title>Calibration curve preparation</title><p>Standard stock solutions were prepared in MeOH containing butylated hydroxytoluene (0.4 mg/ml). A calibration stock was made with concentrations found in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for the prostaglandins, isopostranes, LPAs, sphingolipids and PAF available base standards and was labeled ‘C9’. This solution was diluted to levels C8 to C1 and from these mixes, 20 µl was added to 150 ul sample to construct the calibration curves.</p></sec><sec id="s3-5"><title>Data pre-processing</title><p>LabSolutions (Shimadzu, Version 5.91) was applied to accomplish all the peak determination and integration. For each metabolite, the response ratio was obtained by calculating the ratio of peak area of the target compound to the peak area of the assigned internal standard. After QC evaluation, metabolites of which QC samples had an RSD less than 30% were used for further statistical analysis. Finally, the absolute concentration of the targets was determined using the calibration curves.</p></sec><sec id="s3-6"><title>Statistical analysis</title><p>Heatmaps and bar plots were created with GraphPad Prism 7 (GraphPad Software). The fold change was calculated by normalizing the conditions to the control group. Subsequently, the data were log2 transformed and used for the heatmaps. The absolute concentrations of those compounds were visualized in the bar plots. We used IBM SPSS Statistics 23 (IBM) for statistical analyses. Bar plots were plotted as mean ± s.e.m. of three biological replicates per condition; n = 4–6 technical replicates. Significance levels were set at *p&lt;0.1, **p&lt;0.05, ***p&lt;0.01, ****p&lt;0.001 using the unpaired Student’s t-test.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This study was financially supported by the RECONNECT CVON Groot consortium, which is funded by the Dutch Heart Foundation. AJ and TH, AJvZ were supported by a ZonMW MKMD grant (114022501). AM and TH acknowledge the support by the NWO-TTW (IMMUNMET, grant number 16249). TH acknowledge the support by the TKI METABOCHIP project, which is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences &amp; Health, to stimulate public-private partnerships.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>co-founder of MIMETAS and has some shares in MIMETAS.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - review and editing</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Calibration curve of bioactive lipids.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54754-data1-v2.xlsx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>References regarding the action of bioactive lipids on inflammation, platelets, vascular tone and angiogenesis.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-54754-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>An overview of the concentrations of the calibration solution.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-54754-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-54754-transrepform-v2.docx"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>The data used to generate the figures and tables can be found in the source data files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname> <given-names>SJ</given-names></name><name><surname>Park</surname> <given-names>GY</given-names></name><name><surname>Christman</surname> <given-names>JW</given-names></name><name><surname>Nyenhuis</surname> <given-names>S</given-names></name><name><surname>Berdyshev</surname> <given-names>E</given-names></name><name><surname>Natarajan</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Polyunsaturated lysophosphatidic acid as a potential asthma biomarker</article-title><source>Biomarkers in Medicine</source><volume>10</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.2217/bmm.15.93</pub-id><pub-id pub-id-type="pmid">26808693</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname> <given-names>SE</given-names></name><name><surname>Harikumar</surname> <given-names>KB</given-names></name><name><surname>Hait</surname> <given-names>NC</given-names></name><name><surname>Allegood</surname> <given-names>J</given-names></name><name><surname>Strub</surname> <given-names>GM</given-names></name><name><surname>Kim</surname> <given-names>EY</given-names></name><name><surname>Maceyka</surname> <given-names>M</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Luo</surname> <given-names>C</given-names></name><name><surname>Kordula</surname> <given-names>T</given-names></name><name><surname>Milstien</surname> <given-names>S</given-names></name><name><surname>Spiegel</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2</article-title><source>Nature</source><volume>465</volume><fpage>1084</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1038/nature09128</pub-id><pub-id pub-id-type="pmid">20577214</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeyens</surname> <given-names>N</given-names></name><name><surname>Bandyopadhyay</surname> <given-names>C</given-names></name><name><surname>Coon</surname> <given-names>BG</given-names></name><name><surname>Yun</surname> <given-names>S</given-names></name><name><surname>Schwartz</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial fluid shear stress sensing in vascular health and disease</article-title><source>Journal of Clinical Investigation</source><volume>126</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1172/JCI83083</pub-id><pub-id pub-id-type="pmid">26928035</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagyalakshmi</surname> <given-names>A</given-names></name><name><surname>Berthiaume</surname> <given-names>F</given-names></name><name><surname>Reich</surname> <given-names>KM</given-names></name><name><surname>Frangos</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Fluid shear stress stimulates membrane phospholipid metabolism in cultured human endothelial cells</article-title><source>Journal of Vascular Research</source><volume>29</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1159/000158963</pub-id><pub-id pub-id-type="pmid">1489890</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biermann</surname> <given-names>D</given-names></name><name><surname>Heilmann</surname> <given-names>A</given-names></name><name><surname>Didié</surname> <given-names>M</given-names></name><name><surname>Schlossarek</surname> <given-names>S</given-names></name><name><surname>Wahab</surname> <given-names>A</given-names></name><name><surname>Grimm</surname> <given-names>M</given-names></name><name><surname>Römer</surname> <given-names>M</given-names></name><name><surname>Reichenspurner</surname> <given-names>H</given-names></name><name><surname>Sultan</surname> <given-names>KR</given-names></name><name><surname>Steenpass</surname> <given-names>A</given-names></name><name><surname>Ergün</surname> <given-names>S</given-names></name><name><surname>Donzelli</surname> <given-names>S</given-names></name><name><surname>Carrier</surname> <given-names>L</given-names></name><name><surname>Ehmke</surname> <given-names>H</given-names></name><name><surname>Zimmermann</surname> <given-names>WH</given-names></name><name><surname>Hein</surname> <given-names>L</given-names></name><name><surname>Böger</surname> <given-names>RH</given-names></name><name><surname>Benndorf</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Impact of AT2 receptor deficiency on postnatal cardiovascular development</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e47916</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047916</pub-id><pub-id pub-id-type="pmid">23144713</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaser</surname> <given-names>H</given-names></name><name><surname>Dostert</surname> <given-names>C</given-names></name><name><surname>Mak</surname> <given-names>TW</given-names></name><name><surname>Brenner</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TNF and ROS crosstalk in inflammation</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.12.002</pub-id><pub-id pub-id-type="pmid">26791157</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>H</given-names></name><name><surname>Harrison</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress</article-title><source>Circulation Research</source><volume>87</volume><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1161/01.RES.87.10.840</pub-id><pub-id pub-id-type="pmid">11073878</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>MS</given-names></name><name><surname>Chen</surname> <given-names>BC</given-names></name><name><surname>Yu</surname> <given-names>MT</given-names></name><name><surname>Sheu</surname> <given-names>JR</given-names></name><name><surname>Chen</surname> <given-names>TF</given-names></name><name><surname>Lin</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK, pathways</article-title><source>Cellular Signalling</source><volume>17</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2004.07.008</pub-id><pub-id pub-id-type="pmid">15567061</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimen</surname> <given-names>M</given-names></name><name><surname>Yates</surname> <given-names>CM</given-names></name><name><surname>McGettrick</surname> <given-names>HM</given-names></name><name><surname>Ward</surname> <given-names>LS</given-names></name><name><surname>Harrison</surname> <given-names>MJ</given-names></name><name><surname>Apta</surname> <given-names>B</given-names></name><name><surname>Dib</surname> <given-names>LH</given-names></name><name><surname>Imhof</surname> <given-names>BA</given-names></name><name><surname>Harrison</surname> <given-names>P</given-names></name><name><surname>Nash</surname> <given-names>GB</given-names></name><name><surname>Rainger</surname> <given-names>GE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monocyte subsets coregulate inflammatory responses by integrated signaling through TNF and IL-6 at the endothelial cell interface</article-title><source>The Journal of Immunology</source><volume>198</volume><fpage>2834</fpage><lpage>2843</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601281</pub-id><pub-id pub-id-type="pmid">28193827</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duracková</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Some current insights into oxidative stress</article-title><source>Physiological Research</source><volume>59</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">19929132</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworski</surname> <given-names>R</given-names></name><name><surname>Roberts</surname> <given-names>LJ</given-names></name><name><surname>Murray</surname> <given-names>JJ</given-names></name><name><surname>Morrow</surname> <given-names>JD</given-names></name><name><surname>Hartert</surname> <given-names>TV</given-names></name><name><surname>Sheller</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha)</article-title><source>Clinical Experimental Allergy</source><volume>31</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2001.01055.x</pub-id><pub-id pub-id-type="pmid">11260149</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial dysfunction in obesity</article-title><source>Advances in Experimental Medicine and Biology</source><volume>960</volume><fpage>345</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-48382-5_15</pub-id><pub-id pub-id-type="pmid">28585207</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname> <given-names>E</given-names></name><name><surname>Cuzzocrea</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma</article-title><source>Current Medicinal Chemistry</source><volume>16</volume><fpage>3152</fpage><lpage>3167</lpage><pub-id pub-id-type="doi">10.2174/092986709788803024</pub-id><pub-id pub-id-type="pmid">19689289</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gezginci-Oktayoglu</surname> <given-names>S</given-names></name><name><surname>Orhan</surname> <given-names>N</given-names></name><name><surname>Bolkent</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prostaglandin-E1 has a protective effect on renal ischemia/reperfusion-induced oxidative stress and inflammation mediated gastric damage in rats</article-title><source>International Immunopharmacology</source><volume>36</volume><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2016.04.021</pub-id><pub-id pub-id-type="pmid">27135545</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>LA</given-names></name><name><surname>Njoku</surname> <given-names>V</given-names></name><name><surname>Mund</surname> <given-names>J</given-names></name><name><surname>Case</surname> <given-names>J</given-names></name><name><surname>Yoder</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>MP</given-names></name><name><surname>Clauss</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endogenous transmembrane TNF-Alpha protects against premature senescence in endothelial colony forming cells</article-title><source>Circulation Research</source><volume>118</volume><fpage>1512</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308332</pub-id><pub-id pub-id-type="pmid">27076598</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huveneers</surname> <given-names>S</given-names></name><name><surname>Daemen</surname> <given-names>MJ</given-names></name><name><surname>Hordijk</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Between rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease</article-title><source>Circulation Research</source><volume>116</volume><fpage>895</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305720</pub-id><pub-id pub-id-type="pmid">25722443</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffe</surname> <given-names>EA</given-names></name><name><surname>Nachman</surname> <given-names>RL</given-names></name><name><surname>Becker</surname> <given-names>CG</given-names></name><name><surname>Minick</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Culture of human endothelial cells derived from umbilical veins. identification by morphologic and immunologic criteria</article-title><source>Journal of Clinical Investigation</source><volume>52</volume><fpage>2745</fpage><lpage>2756</lpage><pub-id pub-id-type="doi">10.1172/JCI107470</pub-id><pub-id pub-id-type="pmid">4355998</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karshovska</surname> <given-names>E</given-names></name><name><surname>Mohibullah</surname> <given-names>R</given-names></name><name><surname>Zahedi</surname> <given-names>F</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Ferreiros</surname> <given-names>N</given-names></name><name><surname>Schober</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>P6569Endothelial specific autotaxin in atherosclerosis</article-title><source>European Heart Journal</source><volume>39</volume><fpage>1404</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehy566.P6569</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandoga</surname> <given-names>AL</given-names></name><name><surname>Fujiwara</surname> <given-names>Y</given-names></name><name><surname>Goyal</surname> <given-names>P</given-names></name><name><surname>Pandey</surname> <given-names>D</given-names></name><name><surname>Tsukahara</surname> <given-names>R</given-names></name><name><surname>Bolen</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Wilke</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Valentine</surname> <given-names>WJ</given-names></name><name><surname>Durgam</surname> <given-names>GG</given-names></name><name><surname>Miller</surname> <given-names>DD</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Prestwich</surname> <given-names>GD</given-names></name><name><surname>Tigyi</surname> <given-names>G</given-names></name><name><surname>Siess</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin</article-title><source>Platelets</source><volume>19</volume><fpage>415</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1080/09537100802220468</pub-id><pub-id pub-id-type="pmid">18925509</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsiaris</surname> <given-names>AG</given-names></name><name><surname>Tachmitzi</surname> <given-names>SV</given-names></name><name><surname>Batis</surname> <given-names>N</given-names></name><name><surname>Kotoula</surname> <given-names>MG</given-names></name><name><surname>Karabatsas</surname> <given-names>CH</given-names></name><name><surname>Tsironi</surname> <given-names>E</given-names></name><name><surname>Chatzoulis</surname> <given-names>DZ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Volume flow and wall shear stress quantification in the human conjunctival capillaries and post-capillary venules in vivo</article-title><source>Biorheology</source><volume>44</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">18401076</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Lilly</surname> <given-names>GD</given-names></name><name><surname>Doty</surname> <given-names>RC</given-names></name><name><surname>Podsiadlo</surname> <given-names>P</given-names></name><name><surname>Kotov</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>In vitro toxicity testing of nanoparticles in 3D cell culture</article-title><source>Small</source><volume>424</volume><fpage>1213</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1002/smll.200801788</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>Y-li</given-names></name><name><surname>Liao</surname> <given-names>X</given-names></name><name><surname>Ouyang</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RhoA and membrane fluidity mediates the spatially polarized src/FAK activation in response to shear stress</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>07008</elocation-id><pub-id pub-id-type="doi">10.1038/srep07008</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname> <given-names>S</given-names></name><name><surname>Orlandi</surname> <given-names>M</given-names></name><name><surname>Parkar</surname> <given-names>M</given-names></name><name><surname>Bhowruth</surname> <given-names>D</given-names></name><name><surname>Kingston</surname> <given-names>I</given-names></name><name><surname>O'Rourke</surname> <given-names>C</given-names></name><name><surname>Virdis</surname> <given-names>A</given-names></name><name><surname>Hingorani</surname> <given-names>A</given-names></name><name><surname>Hurel</surname> <given-names>SJ</given-names></name><name><surname>Donos</surname> <given-names>N</given-names></name><name><surname>D'Aiuto</surname> <given-names>F</given-names></name><name><surname>Deanfield</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: a randomised controlled clinical trial</article-title><source>International Journal of Cardiology</source><volume>271</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.05.019</pub-id><pub-id pub-id-type="pmid">30077530</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname> <given-names>JD</given-names></name><name><surname>Hill</surname> <given-names>KE</given-names></name><name><surname>Burk</surname> <given-names>RF</given-names></name><name><surname>Nammour</surname> <given-names>TM</given-names></name><name><surname>Badr</surname> <given-names>KF</given-names></name><name><surname>Roberts</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism</article-title><source>PNAS</source><volume>87</volume><fpage>9383</fpage><lpage>9387</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.23.9383</pub-id><pub-id pub-id-type="pmid">2123555</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutzouri</surname> <given-names>E</given-names></name><name><surname>Liberopoulos</surname> <given-names>EN</given-names></name><name><surname>Tellis</surname> <given-names>CC</given-names></name><name><surname>Milionis</surname> <given-names>HJ</given-names></name><name><surname>Tselepis</surname> <given-names>AD</given-names></name><name><surname>Elisaf</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia</article-title><source>Atherosclerosis</source><volume>231</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.08.013</pub-id><pub-id pub-id-type="pmid">24125402</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname> <given-names>J</given-names></name><name><surname>Kessinger</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Effects of 8-Isoprostaglandin E1 on the systemic and pulmonary circulations in dogs</article-title><source>Experimental Biology and Medicine</source><volume>133</volume><fpage>1314</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.3181/00379727-133-34679</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninou</surname> <given-names>I</given-names></name><name><surname>Magkrioti</surname> <given-names>C</given-names></name><name><surname>Aidinis</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autotaxin in pathophysiology and pulmonary fibrosis</article-title><source>Frontiers in Medicine</source><volume>5</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2018.00180</pub-id><pub-id pub-id-type="pmid">29951481</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohmura</surname> <given-names>T</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Sarich</surname> <given-names>N</given-names></name><name><surname>Ke</surname> <given-names>Y</given-names></name><name><surname>Meliton</surname> <given-names>A</given-names></name><name><surname>Shah</surname> <given-names>AS</given-names></name><name><surname>Andreasson</surname> <given-names>K</given-names></name><name><surname>Birukov</surname> <given-names>KG</given-names></name><name><surname>Birukova</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor</article-title><source>Molecular Biology of the Cell</source><volume>28</volume><fpage>1622</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1091/mbc.e16-09-0639</pub-id><pub-id pub-id-type="pmid">28428256</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmetshofer</surname> <given-names>A</given-names></name><name><surname>Robson</surname> <given-names>SC</given-names></name><name><surname>Nehls</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells</article-title><source>Thrombosis and Haemostasis</source><volume>82</volume><fpage>1532</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1614867</pub-id><pub-id pub-id-type="pmid">10595650</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palur Ramakrishnan</surname> <given-names>AV</given-names></name><name><surname>Varghese</surname> <given-names>TP</given-names></name><name><surname>Vanapalli</surname> <given-names>S</given-names></name><name><surname>Nair</surname> <given-names>NK</given-names></name><name><surname>Mingate</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Platelet activating factor: a potential biomarker in acute coronary syndrome?</article-title><source>Cardiovascular Therapeutics</source><volume>35</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/1755-5922.12233</pub-id><pub-id pub-id-type="pmid">27790832</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisoschi</surname> <given-names>AM</given-names></name><name><surname>Pop</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of antioxidants in the chemistry of oxidative stress: a review</article-title><source>European Journal of Medicinal Chemistry</source><volume>97</volume><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.04.040</pub-id><pub-id pub-id-type="pmid">25942353</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poussin</surname> <given-names>C</given-names></name><name><surname>Kramer</surname> <given-names>B</given-names></name><name><surname>Lanz</surname> <given-names>HL</given-names></name><name><surname>Van den Heuvel</surname> <given-names>A</given-names></name><name><surname>Laurent</surname> <given-names>A</given-names></name><name><surname>Olivier</surname> <given-names>T</given-names></name><name><surname>Vermeer</surname> <given-names>M</given-names></name><name><surname>Peric</surname> <given-names>D</given-names></name><name><surname>Baumer</surname> <given-names>K</given-names></name><name><surname>Dulize</surname> <given-names>R</given-names></name><name><surname>Guedj</surname> <given-names>E</given-names></name><name><surname>Ivanov</surname> <given-names>NV</given-names></name><name><surname>Peitsch</surname> <given-names>MC</given-names></name><name><surname>Hoeng</surname> <given-names>J</given-names></name><name><surname>Joore</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>3d human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow - application in systems toxicology</article-title><source>Altex</source><volume>37</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.14573/altex.1811301</pub-id><pub-id pub-id-type="pmid">31445503</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabelink</surname> <given-names>TJ</given-names></name><name><surname>de Boer</surname> <given-names>HC</given-names></name><name><surname>van Zonneveld</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Endothelial activation and circulating markers of endothelial activation in kidney disease</article-title><source>Nature Reviews Nephrology</source><volume>6</volume><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2010.65</pub-id><pub-id pub-id-type="pmid">20498676</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Established and emerging plasma biomarkers in the prediction of first atherothrombotic events</article-title><source>Circulation</source><volume>109</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000133444.17867.56</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rokach</surname> <given-names>J</given-names></name><name><surname>Khanapure</surname> <given-names>SP</given-names></name><name><surname>Hwang</surname> <given-names>SW</given-names></name><name><surname>Adiyaman</surname> <given-names>M</given-names></name><name><surname>Lawson</surname> <given-names>JA</given-names></name><name><surname>FitzGerald</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The isoprostanes: a perspective</article-title><source>Prostaglandins</source><volume>54</volume><fpage>823</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1016/S0090-6980(97)00183-4</pub-id><pub-id pub-id-type="pmid">9533180</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname> <given-names>Y</given-names></name><name><surname>Reid</surname> <given-names>MJ</given-names></name><name><surname>Thomas</surname> <given-names>KV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Liquid chromatography-high resolution mass spectrometry with immunoaffinity clean-up for the determination of the oxidative stress biomarker 8-iso-prostaglandin F2alpha in wastewater</article-title><source>Journal of Chromatography A</source><volume>1409</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2015.07.060</pub-id><pub-id pub-id-type="pmid">26231523</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoeman</surname> <given-names>JC</given-names></name><name><surname>Harms</surname> <given-names>AC</given-names></name><name><surname>van Weeghel</surname> <given-names>M</given-names></name><name><surname>Berger</surname> <given-names>R</given-names></name><name><surname>Vreeken</surname> <given-names>RJ</given-names></name><name><surname>Hankemeier</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Development and application of a UHPLC-MS/MS metabolomics based comprehensive systemic and tissue-specific screening method for inflammatory, oxidative and nitrosative stress</article-title><source>Analytical and Bioanalytical Chemistry</source><volume>410</volume><fpage>2551</fpage><lpage>2568</lpage><pub-id pub-id-type="doi">10.1007/s00216-018-0912-2</pub-id><pub-id pub-id-type="pmid">29497765</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>E</given-names></name><name><surname>Gori</surname> <given-names>T</given-names></name><name><surname>Münzel</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oxidative stress and endothelial dysfunction in hypertension</article-title><source>Hypertension Research</source><volume>34</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/hr.2011.39</pub-id><pub-id pub-id-type="pmid">21512515</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedger</surname> <given-names>LM</given-names></name><name><surname>McDermott</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>25</volume><fpage>453</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.07.016</pub-id><pub-id pub-id-type="pmid">25169849</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraki</surname> <given-names>A</given-names></name><name><surname>Oyama</surname> <given-names>J</given-names></name><name><surname>Komoda</surname> <given-names>H</given-names></name><name><surname>Asaka</surname> <given-names>M</given-names></name><name><surname>Komatsu</surname> <given-names>A</given-names></name><name><surname>Sakuma</surname> <given-names>M</given-names></name><name><surname>Kodama</surname> <given-names>K</given-names></name><name><surname>Sakamoto</surname> <given-names>Y</given-names></name><name><surname>Kotooka</surname> <given-names>N</given-names></name><name><surname>Hirase</surname> <given-names>T</given-names></name><name><surname>Node</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells</article-title><source>Atherosclerosis</source><volume>221</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.12.039</pub-id><pub-id pub-id-type="pmid">22284365</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroka</surname> <given-names>KM</given-names></name><name><surname>Aranda-Espinoza</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endothelial cell substrate stiffness influences neutrophil transmigration via myosin light chain kinase-dependent cell contraction</article-title><source>Blood</source><volume>118</volume><fpage>1632</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-11-321125</pub-id><pub-id pub-id-type="pmid">21652678</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Castro</surname> <given-names>I</given-names></name><name><surname>Arroyo-Camarena</surname> <given-names>ÚD</given-names></name><name><surname>Martínez-Reyes</surname> <given-names>CP</given-names></name><name><surname>Gómez-Arauz</surname> <given-names>AY</given-names></name><name><surname>Dueñas-Andrade</surname> <given-names>Y</given-names></name><name><surname>Hernández-Ruiz</surname> <given-names>J</given-names></name><name><surname>Béjar</surname> <given-names>YL</given-names></name><name><surname>Zaga-Clavellina</surname> <given-names>V</given-names></name><name><surname>Morales-Montor</surname> <given-names>J</given-names></name><name><surname>Terrazas</surname> <given-names>LI</given-names></name><name><surname>Kzhyshkowska</surname> <given-names>J</given-names></name><name><surname>Escobedo</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose</article-title><source>Immunology Letters</source><volume>176</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2016.06.001</pub-id><pub-id pub-id-type="pmid">27269375</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebatická</surname> <given-names>J</given-names></name><name><surname>Dukát</surname> <given-names>A</given-names></name><name><surname>Ďuračková</surname> <given-names>Z</given-names></name><name><surname>Muchová</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids</article-title><source>Physiological Research</source><volume>66</volume><fpage>363</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.33549/physiolres.933430</pub-id><pub-id pub-id-type="pmid">28248536</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname> <given-names>T</given-names></name><name><surname>Haniu</surname> <given-names>H</given-names></name><name><surname>Matsuda</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells</article-title><source>International Journal of Medical Sciences</source><volume>11</volume><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.7150/ijms.9316</pub-id><pub-id pub-id-type="pmid">25013374</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Duinen</surname> <given-names>V</given-names></name><name><surname>van den Heuvel</surname> <given-names>A</given-names></name><name><surname>Trietsch</surname> <given-names>SJ</given-names></name><name><surname>Lanz</surname> <given-names>HL</given-names></name><name><surname>van Gils</surname> <given-names>JM</given-names></name><name><surname>van Zonneveld</surname> <given-names>AJ</given-names></name><name><surname>Vulto</surname> <given-names>P</given-names></name><name><surname>Hankemeier</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>96 perfusable blood vessels to study vascular permeability in vitro</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>18071</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-14716-y</pub-id><pub-id pub-id-type="pmid">29273771</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zonneveld</surname> <given-names>AJ</given-names></name><name><surname>de Boer</surname> <given-names>HC</given-names></name><name><surname>van der Veer</surname> <given-names>EP</given-names></name><name><surname>Rabelink</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inflammation, vascular injury and repair in rheumatoid arthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>69</volume><fpage>i57</fpage><lpage>i60</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.119495</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassalle</surname> <given-names>C</given-names></name><name><surname>Petrozzi</surname> <given-names>L</given-names></name><name><surname>Botto</surname> <given-names>N</given-names></name><name><surname>Andreassi</surname> <given-names>MG</given-names></name><name><surname>Zucchelli</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Oxidative stress and its association with coronary artery disease and different atherogenic risk factors</article-title><source>Journal of Internal Medicine</source><volume>256</volume><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01373.x</pub-id><pub-id pub-id-type="pmid">15367173</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vulto</surname> <given-names>P</given-names></name><name><surname>Podszun</surname> <given-names>S</given-names></name><name><surname>Meyer</surname> <given-names>P</given-names></name><name><surname>Hermann</surname> <given-names>C</given-names></name><name><surname>Manz</surname> <given-names>A</given-names></name><name><surname>Urban</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Phaseguides: a paradigm shift in microfluidic priming and emptying</article-title><source>Lab on a Chip</source><volume>11</volume><fpage>1596</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1039/c0lc00643b</pub-id><pub-id pub-id-type="pmid">21394334</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wevers</surname> <given-names>NR</given-names></name><name><surname>Kasi</surname> <given-names>DG</given-names></name><name><surname>Gray</surname> <given-names>T</given-names></name><name><surname>Wilschut</surname> <given-names>KJ</given-names></name><name><surname>Smith</surname> <given-names>B</given-names></name><name><surname>van Vught</surname> <given-names>R</given-names></name><name><surname>Shimizu</surname> <given-names>F</given-names></name><name><surname>Sano</surname> <given-names>Y</given-names></name><name><surname>Kanda</surname> <given-names>T</given-names></name><name><surname>Marsh</surname> <given-names>G</given-names></name><name><surname>Trietsch</surname> <given-names>SJ</given-names></name><name><surname>Vulto</surname> <given-names>P</given-names></name><name><surname>Lanz</surname> <given-names>HL</given-names></name><name><surname>Obermeier</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport</article-title><source>Fluids and Barriers of the CNS</source><volume>15</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/s12987-018-0108-3</pub-id><pub-id pub-id-type="pmid">30165870</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname> <given-names>DS</given-names></name><name><surname>Tzur</surname> <given-names>D</given-names></name><name><surname>Knox</surname> <given-names>C</given-names></name><name><surname>Eisner</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>AC</given-names></name><name><surname>Young</surname> <given-names>N</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Jewell</surname> <given-names>K</given-names></name><name><surname>Arndt</surname> <given-names>D</given-names></name><name><surname>Sawhney</surname> <given-names>S</given-names></name><name><surname>Fung</surname> <given-names>C</given-names></name><name><surname>Nikolai</surname> <given-names>L</given-names></name><name><surname>Lewis</surname> <given-names>M</given-names></name><name><surname>Coutouly</surname> <given-names>MA</given-names></name><name><surname>Forsythe</surname> <given-names>I</given-names></name><name><surname>Tang</surname> <given-names>P</given-names></name><name><surname>Shrivastava</surname> <given-names>S</given-names></name><name><surname>Jeroncic</surname> <given-names>K</given-names></name><name><surname>Stothard</surname> <given-names>P</given-names></name><name><surname>Amegbey</surname> <given-names>G</given-names></name><name><surname>Block</surname> <given-names>D</given-names></name><name><surname>Hau</surname> <given-names>DD</given-names></name><name><surname>Wagner</surname> <given-names>J</given-names></name><name><surname>Miniaci</surname> <given-names>J</given-names></name><name><surname>Clements</surname> <given-names>M</given-names></name><name><surname>Gebremedhin</surname> <given-names>M</given-names></name><name><surname>Guo</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Duggan</surname> <given-names>GE</given-names></name><name><surname>Macinnis</surname> <given-names>GD</given-names></name><name><surname>Weljie</surname> <given-names>AM</given-names></name><name><surname>Dowlatabadi</surname> <given-names>R</given-names></name><name><surname>Bamforth</surname> <given-names>F</given-names></name><name><surname>Clive</surname> <given-names>D</given-names></name><name><surname>Greiner</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Marrie</surname> <given-names>T</given-names></name><name><surname>Sykes</surname> <given-names>BD</given-names></name><name><surname>Vogel</surname> <given-names>HJ</given-names></name><name><surname>Querengesser</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>HMDB: the human metabolome database</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>D521</fpage><lpage>D526</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl923</pub-id><pub-id pub-id-type="pmid">17202168</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname> <given-names>DS</given-names></name><name><surname>Knox</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>AC</given-names></name><name><surname>Eisner</surname> <given-names>R</given-names></name><name><surname>Young</surname> <given-names>N</given-names></name><name><surname>Gautam</surname> <given-names>B</given-names></name><name><surname>Hau</surname> <given-names>DD</given-names></name><name><surname>Psychogios</surname> <given-names>N</given-names></name><name><surname>Dong</surname> <given-names>E</given-names></name><name><surname>Bouatra</surname> <given-names>S</given-names></name><name><surname>Mandal</surname> <given-names>R</given-names></name><name><surname>Sinelnikov</surname> <given-names>I</given-names></name><name><surname>Xia</surname> <given-names>J</given-names></name><name><surname>Jia</surname> <given-names>L</given-names></name><name><surname>Cruz</surname> <given-names>JA</given-names></name><name><surname>Lim</surname> <given-names>E</given-names></name><name><surname>Sobsey</surname> <given-names>CA</given-names></name><name><surname>Shrivastava</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Fang</surname> <given-names>L</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Fradette</surname> <given-names>R</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Tzur</surname> <given-names>D</given-names></name><name><surname>Clements</surname> <given-names>M</given-names></name><name><surname>Lewis</surname> <given-names>A</given-names></name><name><surname>De Souza</surname> <given-names>A</given-names></name><name><surname>Zuniga</surname> <given-names>A</given-names></name><name><surname>Dawe</surname> <given-names>M</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Clive</surname> <given-names>D</given-names></name><name><surname>Greiner</surname> <given-names>R</given-names></name><name><surname>Nazyrova</surname> <given-names>A</given-names></name><name><surname>Shaykhutdinov</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Vogel</surname> <given-names>HJ</given-names></name><name><surname>Forsythe</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HMDB: a knowledgebase for the human metabolome</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>D603</fpage><lpage>D610</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn810</pub-id><pub-id pub-id-type="pmid">18953024</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname> <given-names>DS</given-names></name><name><surname>Jewison</surname> <given-names>T</given-names></name><name><surname>Guo</surname> <given-names>AC</given-names></name><name><surname>Wilson</surname> <given-names>M</given-names></name><name><surname>Knox</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Djoumbou</surname> <given-names>Y</given-names></name><name><surname>Mandal</surname> <given-names>R</given-names></name><name><surname>Aziat</surname> <given-names>F</given-names></name><name><surname>Dong</surname> <given-names>E</given-names></name><name><surname>Bouatra</surname> <given-names>S</given-names></name><name><surname>Sinelnikov</surname> <given-names>I</given-names></name><name><surname>Arndt</surname> <given-names>D</given-names></name><name><surname>Xia</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Yallou</surname> <given-names>F</given-names></name><name><surname>Bjorndahl</surname> <given-names>T</given-names></name><name><surname>Perez-Pineiro</surname> <given-names>R</given-names></name><name><surname>Eisner</surname> <given-names>R</given-names></name><name><surname>Allen</surname> <given-names>F</given-names></name><name><surname>Neveu</surname> <given-names>V</given-names></name><name><surname>Greiner</surname> <given-names>R</given-names></name><name><surname>Scalbert</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HMDB 3.0--the human metabolome database in 2013</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D801</fpage><lpage>D807</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1065</pub-id><pub-id pub-id-type="pmid">23161693</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname> <given-names>DS</given-names></name><name><surname>Feunang</surname> <given-names>YD</given-names></name><name><surname>Marcu</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>AC</given-names></name><name><surname>Liang</surname> <given-names>K</given-names></name><name><surname>Vázquez-Fresno</surname> <given-names>R</given-names></name><name><surname>Sajed</surname> <given-names>T</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Karu</surname> <given-names>N</given-names></name><name><surname>Sayeeda</surname> <given-names>Z</given-names></name><name><surname>Lo</surname> <given-names>E</given-names></name><name><surname>Assempour</surname> <given-names>N</given-names></name><name><surname>Berjanskii</surname> <given-names>M</given-names></name><name><surname>Singhal</surname> <given-names>S</given-names></name><name><surname>Arndt</surname> <given-names>D</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>Badran</surname> <given-names>H</given-names></name><name><surname>Grant</surname> <given-names>J</given-names></name><name><surname>Serra-Cayuela</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Mandal</surname> <given-names>R</given-names></name><name><surname>Neveu</surname> <given-names>V</given-names></name><name><surname>Pon</surname> <given-names>A</given-names></name><name><surname>Knox</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>M</given-names></name><name><surname>Manach</surname> <given-names>C</given-names></name><name><surname>Scalbert</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HMDB 4.0: the human metabolome database for 2018</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D608</fpage><lpage>D617</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1089</pub-id><pub-id pub-id-type="pmid">29140435</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>MS</given-names></name><name><surname>Vanhoutte</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>COX-mediated endothelium-dependent contractions: from the past to recent discoveries</article-title><source>Acta Pharmacologica Sinica</source><volume>31</volume><fpage>1095</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1038/aps.2010.127</pub-id><pub-id pub-id-type="pmid">20711228</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>B</given-names></name><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Niu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The effect of lysophosphatidic acid on Toll-like receptor 4 expression and the nuclear factor-κB signaling pathway in THP-1 cells</article-title><source>Molecular and Cellular Biochemistry</source><volume>422</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s11010-016-2804-0</pub-id><pub-id pub-id-type="pmid">27619660</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54754.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Mangoni</surname><given-names>Arduino A</given-names></name><role>Reviewing Editor</role><aff><institution>Flinders Medical Centre</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dunn</surname><given-names>Warwick</given-names> </name><role>Reviewer</role><aff><institution/><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The study integrates two new and innovative technologies [use of 1) a 3-D cell culture model and 2) metabolites across different lipid classes] as an in vitro model to investigate the metabolic effects of TNF-α on blood vessels. The results of the study provide important new tools and insights into blood vessels and how they operate under different inflammatory burden.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Metabolic response of blood vessels to TNFα&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Matthias Barton as the Senior Editor. The following individual involved in reviewing your submission has agreed to reveal their identity: Warwick Dunn (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The study integrates two innovative technologies [use of 1) a 3-D cell model and 2) metabolites across different lipid classes] to investigate the metabolic effects of TNF-α on blood vessels. The results of the study provide important new tools and insights into blood vessels and how they operate under different inflammatory burden.</p><p>Essential revisions:</p><p>– Absolute concentration of the lipids measured should be shown. The log 2 ratios in the comparisons in tables are frequently negative, which may suggest that detected amounts are very low. The use of a microchip with flow in low volumes may be a challenge to detect metabolites. It would also be important to compare the absolute levels detected in the in vitro model to what is observed in vivo.</p><p>– The number of replicates analysed appears to be mostly 2 after pooling of samples; this provides a limitation of the manuscript. According to the authors, &quot;Bar plots were plotted as mean ± SEM of two or three technical replicates. Significance levels were set at *p &lt; 0.05 using the Mann-Whitney U test.&quot; In Supplementary Figure 1, however, the n number given is 4. The authors used only n=2 in most of the experiments after pooling from several samples. According to the authors the &quot;Mann-Whitney U test&quot; was used to calculate statistical comparisons, a test that applies to data with non-parametric distribution. Distribution of the data indicated by the error bars in many experiments suggests parametric distribution. An n=2 of replicates does neither allows to determine data distribution nor normality/non-normality, let alone to choose the appropriate statistical test. In view of this and given the fact that individual replicates were pooled from more samples it is recommended that the authors consult a biostatistician regarding how to best compare and analyse these data and add this new information to the manuscript. Alternatively, either the replicates for each experiment would need to be increased to an n number sufficient to determine distribution normality and to apply the corresponding test, or any information indicating statistical significances would need to be removed.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54754.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>– Absolute concentration of the lipids measured should be shown. The log 2 ratios in the comparisons in tables are frequently negative, which may suggest that detected amounts are very low. The use of a microchip with flow in low volumes may be a challenge to detect metabolites. It would also be important to compare the absolute levels detected in the in vitro model to what is observed in vivo.</p></disp-quote><p>We have now included the absolute concentration of the lipids. This is shown in Figure 3 and an explanation regarding the calibration curve is given in the Materials and methods section. Furthermore, we compared the absolute concentrations of some of the detected targets in our microvessels-on-a-chip with what is observed in vivo. This is shown in Table 2.</p><disp-quote content-type="editor-comment"><p>– The number of replicates analysed appears to be mostly 2 after pooling of samples; this provides a limitation of the manuscript. According to the authors, &quot;Bar plots were plotted as mean ± SEM of two or three technical replicates. Significance levels were set at *p &lt; 0.05 using the Mann-Whitney U test.&quot; In Supplementary Figure 1, however, the n number given is 4. The authors used only n=2 in most of the experiments after pooling from several samples. According to the authors the &quot;Mann-Whitney U test&quot; was used to calculate statistical comparisons, a test that applies to data with non-parametric distribution. Distribution of the data indicated by the error bars in many experiments suggests parametric distribution. An n=2 of replicates does neither allows to determine data distribution nor normality/non-normality, let alone to choose the appropriate statistical test. In view of this and given the fact that individual replicates were pooled from more samples it is recommended that the authors consult a biostatistician regarding how to best compare and analyse these data and add this new information to the manuscript. Alternatively, either the replicates for each experiment would need to be increased to an n number sufficient to determine distribution normality and to apply the corresponding test, or any information indicating statistical significances would need to be removed.</p></disp-quote><p>We agree that the number of replicates after pooling the samples provides a limitation for statistical analysis. In response to this comment, we carried out new experiments with three biological replicates and 4-6 technical replicates. This increased the n number to an extent that is sufficient for reliably using unpaired Student’s t-test on normally distributed data (see Figure 3).</p></body></sub-article></article>